Navigation Links
Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
Date:1/9/2012

VANCOUVER, British Columbia, Jan. 9, 2012 /PRNewswire/ -- Xenon today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop compounds and companion diagnostics for the potential treatment of pain.

"We are delighted to be collaborating with Genentech," said Simon Pimstone, President and CEO of Xenon. "Genentech is among the world's leading biotech companies and an ideal strategic partner for Xenon as we share a common emphasis on using human genetics for drug development.  Further, this collaboration allows Xenon to both deepen and broaden our pipeline of novel medicines in development."

Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products. Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications.  In addition, Xenon will receive royalties on sales of products resulting from the collaboration. 

Michael Hayden, CSO of Xenon added: "This new alliance, which represents our sixth partnership with a major pharmaceutical company to date, once again highlights the keen interest in Xenon's unique genetics approach and in our translational R&D capabilities." 

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

 


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
2. Xenon Announces Appointment of EVP, Research & Development
3. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
4. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
5. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
6. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
7. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
8. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
9. Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care
10. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
11. World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay Southerland ... version at the International Roofing Expo in Orlando, Florida on February 17-19. , ... advanced weather technology in the hands of consumers, roofing contractors, manufacturers and distributors,” ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
Breaking Medicine News(10 mins):